Which statement about bisphosphonate-related dental surgery risk is correct?

• A. There is no impact on dental surgery risk.
• B. Increased risk of bisphosphonate-related osteonecrosis of the jaw; minimize invasive procedures.
• C. Only affects pediatric patients.
• D. Requires immediate drug holiday regardless of treatment plan.

Answer: (B)

Understanding the risk in dental surgery for patients taking bisphosphonates hinges on the fact that these drugs can impair jawbone healing and predispose to osteonecrosis after invasive procedures. Bisphosphonates bind to bone and markedly slow turnover by inhibiting osteoclasts, so healing after tooth extractions, implants, or other surgical trauma can be compromised. The risk is higher with intravenous forms used for cancer, with longer duration and higher potency, and when there are additional factors like infection or corticosteroid use.

Because the danger rises with the invasiveness of the procedure and the therapy context, the best approach is to minimize invasive procedures whenever possible, pursue non-surgical alternatives, and plan any necessary surgery with careful, staged strategies and close coordination with the patient’s medical team. Immediate, universal drug holidays are not appropriate for every patient and depend on individual treatment plans and medical advice.

So, the statement that there is an increased risk of bisphosphonate-related osteonecrosis of the jaw and that invasive procedures should be minimized best reflects the clinical reality.